ASC Methylation and Interleukin-1β Are Associated with Aerobic Capacity in Heart Failure

Brittany Butts¹, Javed Butler², Sandra B Dunbar³, Elizabeth Corwin³, and Rebecca A Gary³

¹Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL
²Division of Cardiology, Stony Brook University, Stony Brook, NY
³Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA

Abstract

Background—Aerobic capacity, as measured by peak oxygen uptake (V̇O₂), is one of the most powerful predictors of prognosis in heart failure (HF). Inflammation is a key factor contributing to alterations in aerobic capacity, and interleukin (IL)-1 cytokines are implicated in this process. The adaptor protein ASC is necessary for inflammasome activation of IL-1β and IL-18. ASC expression is controlled through epigenetic modification; lower ASC methylation is associated with worse outcomes in HF. The purpose of this study is to examine the relationships between ASC methylation, IL-1β, and IL-18 with peak V̇O₂ in persons with HF.

Methods—This study examined the relationship between ASC methylation, IL-1β, and IL-18 with peak V̇O₂ in 54 stable outpatients with HF. All participants were NYHA class II or III, not engaged in an exercise program, and physically able to complete an exercise treadmill test.

Results—Mean peak V̇O₂ was 16.68 ± 4.7 ml/kg/min. Peak V̇O₂ was positively associated with mean percent ASC methylation (r=.47, p=.001) and negatively associated with IL-1β (r=-.38, p=.007). Multiple linear regression models demonstrated that peak V̇O₂ increased by 2.30 ml/kg/min for every 1% increase in ASC methylation and decreased by 1.91 ml/kg/min for every 1 pg/mL increase in plasma IL-1β.

Conclusions—Mean percent ASC methylation and plasma IL-1β levels are associated with clinically meaningful differences in peak V̇O₂ in persons with HF. Inflammasome activation may play a mechanistic role in determining aerobic capacity. ASC methylation is a potentially modifiable mechanism for reducing the inflammatory response, thereby improving aerobic capacity in HF.

Keywords

inflammation; inflammasome; exercise testing; cytokines
**Introduction**

Reduced exercise capacity is a characteristic symptom of heart failure (HF), and is accompanied by dyspnea, fatigue, and muscle weakness, even during low-intensity exercise (2, 39). This exercise intolerance is associated with reduced aerobic capacity and low ventilatory efficiency, leading to decreased functional capacity and poor quality of life (2, 3). Clinical evaluation of aerobic capacity in HF is measured by peak oxygen uptake (VO$_2$), a measure of oxygen consumption during a maximum effort treadmill test, and is a strong prognostic indicator of decompensation and mortality (7).

Aerobic capacity is determined by the integrity of the cardiovascular, respiratory, and skeletal muscle systems, all of which are diminished in HF (15, 24, 39). Inflammation negatively affects cardiac, respiratory, and skeletal muscle pathophysiology (1, 15, 16, 37). Chronic inflammation and increased circulating cytokines contribute to the pathophysiology and worsening of HF by altering cardiac structure and function (22). These inflammatory cytokines also play a role in altering skeletal muscle function due to their catabolic effects (1). Chronic inflammation in HF leads to altered breathing patterns, such as inspiratory muscle weakness (21). Thus, inflammation is a key component of pathophysiological changes that lead to decreased aerobic capacity in persons with HF.

**Inflammation and Peak VO$_2$**

Aerobic capacity is negatively associated with inflammatory cytokines, in both healthy populations and in disease states, such as HF (34). Further, changes in peak VO$_2$ in response to an intervention are accompanied by changes in systemic inflammatory cytokines, such as creaktive protein (30, 34). A two-week treatment with the IL-1 cytokine blocker anakinra demonstrated a reduction in systemic inflammation and improvement in peak VO$_2$ in persons with HF in the absence of an exercise intervention (35, 36). Thus, aerobic capacity in HF may be related to increased circulating IL-1 inflammatory cytokines.

The IL-1 cytokines, IL-1β and IL-18, are activated by the inflammasome, a complex of intracellular interaction proteins that triggers maturation of cytokines to initiate and amplify the inflammatory response (9, 18). The inflammasome is composed of a NOD (nucleotide-binding oligomerization domain)-like receptor, ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), and pro-caspase-1 (9). The activated inflammasome cleaves pro-caspase-1 into the active enzyme caspase-1. Caspase-1, in turn, activates IL-1 cytokines IL-1β and IL-18, by cleavage of pro-IL-1β and pro-IL-18 into active forms (8, 18).

The adaptor protein ASC recruits pro-caspase-1 to the inflammasome complex and is necessary for caspase-1 mediated activation of IL-1β and IL-18 (8). ASC expression is controlled by epigenetic modification via methylation of a CpG island in the promoter region of exon 1 (31). Increased methylation of ASC is associated with decreased plasma IL-1β in persons with HF (10).

Higher percent ASC methylation and lower ASC mRNA expression are positively associated with the six-minute walk test (6MWT) in persons with HF (10). Although the 6MWT has
been shown to be a reliable submaximal measure of functional capacity (5), a measure of maximal aerobic capacity can provide better insight into the functional capacity of an individual with HF. The purpose of this study, therefore, was to examine the relationships between ASC methylation, IL-1β, and IL-18 with peak VO₂ in persons with HF.

Methods

Study Design

This cross-sectional study examined the relationship between ASC methylation and peak VO₂ in stable outpatients with HF. Fifty-four participants were enrolled from multidisciplinary outpatient HF clinics.

Study Sample

Inclusion criteria included: documented medical diagnosis of NYHA class II or III, aged 40-75 years; left ventricular ejection fraction (LVEF) ≥10% documented within the last year by echocardiogram, cardiac catheterization ventriculography, or radionuclide ventriculography; and receiving medication therapy for HF according to the American College of Cardiology/American Heart Association recommendation guidelines, including angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers, beta blockers, and diuretics for participants with reduced ejection fraction (LVEF ≤40%) (40), for at least 8 weeks prior to study enrollment. Exclusion criteria included: medical diagnosis of NYHA class I or IV; change in HF therapy within the previous 8 weeks; worsening HF symptoms within the last 5 days; unstable angina; renal insufficiency (serum creatinine > 3.0 mg/dL); fixed rate pacemaker; uncontrolled hypertension, involved in any structured exercise program or exercising 3 or more times per week for a minimum of 30 minutes; hospitalization within the previous 30 days; and any disorder precluding an exercise treadmill test.

Study Protocol

All studies were performed under research protocols approved by the Institutional Review Boards of Emory University and participating institutions. Subjects were informed of testing protocols and the potential risks and benefits of participation. All participants provided written consent before participation. Blood samples were collected in the morning after an overnight fast. Blood was collected in a vacutainer with EDTA, separated into plasma and buffy coat, and stored at -80°C until analysis.

Measurements

Demographic and Clinical Data—Sociodemographic and clinical variables were obtained from medical records and a self-report questionnaire. Height was measured with a standard stadiometer, without shoes. Weight was measured using a calibrated scale with the participant in light clothing, without shoes. Body mass index (BMI) was calculated by the formula: BMI = (weight in kg)/(height in cm)².

Cardiopulmonary Exercise Stress Test—Aerobic capacity was assessed using the modified Balke maximal symptom-limited treadmill test (4, 14) to determine peak oxygen
consumption (peak $\dot{V}O_2$). Continuous gas exchange (VMAX Spectra 29 CPET Instrument, Yorba Linda, CA), telemetry, blood pressure, rating of perceived exertion, and oxygen saturation were assessed for each patient 1 minute before, continuously during exercise, and 4 minutes after the exercise test according to American Heart Association guidelines (3). The test protocol was as follows: 0% incline at 2.0 mph on motorized treadmill for 3 minutes with an increase in incline of 3.5% every 3 minutes for 18 minutes. At 18 minutes, speed increased to 3.0 mph and incline decreased to 12.5%. No participants progressed beyond this point.

ASC Methylation—Percent methylation of 7 CpG sites in the intron region of ASC was measured as previously reported (10). In brief, genomic DNA from peripheral blood mononuclear cells (PBMCs) was bisulfite treated and amplified by PCR followed by pyrosequencing for methylation quantification. Methylation was analyzed as mean percent methylation.

Cytokines—IL-1$\beta$ and IL-18 were analyzed from plasma that has been separated from collected whole blood and stored at -80°C immediately after collection. Plasma cytokines were measured in duplicate using commercially available ELISA kits (eBioscience). Plates were read on a BioTek microplate reader and analyzed using Gen5 software. Curve fitting was selected among linear, quadratic and 4-point based on the best regression coefficient.

Data Analysis

All data were reviewed for data entry errors, potential outliers, and missing data. Clinical and demographic data were complete, and only participants who completed the study protocol (blood draw, 6MWT, treadmill test, and physical examination) were included in the analysis. Distributions were assessed for deviations from normality. IL-18 did not meet criteria for normality and was log transformed (LN) for statistical analysis. However, non-transformed IL-18 values are presented in descriptive data. Pearson correlation analysis was performed to identify linear associations between variables and identify covariates for further analysis. An unpaired Student's t test was used to determine differences in measures between demographic groups. Linear regression analysis was performed to examine linear relationships between the dependent variable, aerobic capacity (as measured by peak $\dot{V}O_2$), and the independent variables, ASC methylation and cytokines, controlling for covariates. Linear regression analysis was performed using 2 models. Model 1 consisted of the independent and dependent variables, without adjusting for covariates. Model 2 also included covariates (age, gender, LVEF, 6MWT, BMI and medications) based on previous documentation and performance of the data and relationships within this study. The variables included in the final model were selected using stepwise selection with an alpha set at 0.10 to minimize multicollinearity and choose the most parsimonious final model. All analysis was performed using SPSS version 23.
Results

Patient Characteristics

Demographic and clinical data are presented in Table 1. Sixty-three percent of the participants had LVEF <40%. The most common comorbidities were hypertension (N=36, 66.7%), dyslipidemia (N=30, 55.6%), depression (N=20, 37.0%), and diabetes (N=19, 35.2%). One-third of participants (N=16, 29.6%) had a previous MI. Age was positively associated with LVEF among females (r=.36, p=.05) but not among males (r=.25, p=.22). Further, females had higher LVEF as compared to males (38.23 ± 14.9 vs. 29.44 ± 13.6, respectively; t=2.26, p=.03).

Physical Measures

Total treadmill time ranged from 1.8 – 18.3 minutes and peak VO₂ ranged from 7.6 – 29.9 ml/kg/min (Table 2). Males had higher treadmill duration and peak VO₂ as compared to females (Table 2). Peak VO₂ was positively associated with total treadmill time (r=.58, p=<.001) and negatively associated with LVEF (r=-.32, p=.02) and BMI (r=-.31, p=.03).

ASC and Cytokines

ASC and cytokine data are presented in Table 3. Mean percent ASC methylation and IL-1β were not associated with age, gender, or race (Table 4). ASC methylation was negatively associated with IL-1β (r=-.44, p=.001), but not IL-18 (r=-.07, p=.64). Peak VO₂ (Figure 1) was positively associated with mean percent ASC methylation (r=.47, p=.001) and negatively associated with IL-1β (r=-.38, p=.007). No association with aerobic capacity and IL-18 was found.

A multiple linear regression was performed to predict peak VO₂ based on mean percent ASC methylation and plasma IL-1β levels, controlling for covariates (Table 4). The models demonstrated that peak VO₂ increased by 2.30 ml/kg/min for every 1% increase in mean ASC methylation and decreased by 1.91 ml/kg/min for every 1 pg/mL increase in plasma IL-1β, adjusting for LVEF and gender. Gender remained a significant predictor of aerobic capacity in both models, such that male gender contributed to 2.42 ml/kg/min and 2.62 ml/kg/min in the ASC and IL-1β models, respectively.

Discussion

This study demonstrated that the inflammasome pathway may impact aerobic capacity in HF patients and serves to broaden our understanding of the biological determinants of aerobic exercise capacity. Previously, we reported a positive linear association between ASC methylation and 6MWT total distance in a different population of persons with HF (10). Here, we show that ASC methylation is positively related to peak VO₂. In addition, IL-1β had a negative relationship with peak VO₂, suggesting the inflammasome may play a mechanistic role in aerobic capacity in HF. Studies of short-term administration of IL-1β blockade (anakinra) were associated with an increase in peak VO₂ in persons with both HFrEF (36) and HFpEF (35). Analysis of a small subset in the HFrEF study (n=3) demonstrated a decrease in IL-1β with anakinra treatment (36). However, this analysis was
too small to determine statistical significance and was not compared to changes in peak VO₂. Nonetheless, the changes in peak VO₂ after IL-1β blockade implicate this interleukin-1 family cytokine in the pathophysiology of decreased aerobic capacity in HF.

Mean percent ASC methylation was 5.84 ± 0.78, which is similar to our previous results in a different HF population (10). The positive association of ASC methylation and peak VO₂ in this study adds a putative mechanism of epigenetic control of inflammatory gene expression contributing to decreased aerobic capacity in HF. Increased ASC methylation is associated with decreased ASC protein and mRNA expression in HF (10). Further, decreased ASC protein expression is associated with decreased IL-1β in HF (10). In this study, linear regression analysis revealed that mean percent ASC methylation and plasma IL-1β levels are associated with clinically meaningful changes in peak VO₂ in persons with HF. Together, these data suggest inflammasome activation of IL-1β plays a mechanistic role in physiological processes in HF.

Increased ASC methylation was associated with decreased plasma IL-1β. No association was found with ASC methylation and plasma IL-18. These findings are similar to our findings in a previous study (10), and are likely indicative of redundancies in function and activation of IL-18 (6). Unlike IL-1β, IL-18 is not involved in the acute phase response and does not induce systemic inflammatory events, such as neutropenia and fever (32, 33). Monocytes can differentially secrete IL-18 or IL-1β, in response to specific signaling, such as leptin (20). Further, while IL-1β activation is tightly regulated by the inflammasome (19), IL-18 can be activated by non-canonical pathways (caspase-3 and Fas-induced caspase-8) and is regulated by the endogenous inhibitor, IL-18BP (6, 28, 38). Thus, IL-18 may represent a common signal downstream of different inflammatory pathways, and may occasionally function independent of IL-1β activity. Mechanistic and tissue-level studies may provide more insight into this relationship.

Gender differences in HF presentation have been previously reported (11). In particular, females with HF, tend to have higher LVEF and lower peak VO₂ than males (11). Our inclusion criteria for LVEF was ≥10% without an upper limit, leading to the inclusion of persons with preserved ejection fraction. This accounts for the positive association with age among females only, as persons with HF and preserved ejection fraction are largely older women (17). In this study, the effects of gender and LVEF on peak VO₂ were accounted for in the regression analysis. The relationships between ASC methylation and IL-1β with peak VO₂ remained significant when controlling for both gender and LVEF. Thus, ASC methylation and IL-1β appear to influence peak VO₂ independent of gender and LVEF.

No association with ASC methylation and age were found, which is similar to our previous study in persons with HF (10). This is in contrast to a previous study by Nakajima et al (25), who found a difference in levels of ASC methylation between younger and older groups of healthy adults. The age-related changes in DNA methylation in healthy adults may not be relevant in HF, which is characterized by a premature cellular aging due to the physiological and psychological stressors of this chronic disease (13). Thus, while among the general adult population there is a decrease in global DNA methylation with age (23, 29), further studies...
are needed to determine the relationships between epigenetic control of gene expression and age in HF.

Nakajima et al. (25) found no relationship between ASC methylation and \( \dot{V}O_{2\text{max}} \) in their study of healthy adults. This difference in findings reported in the current study may be related to the pathophysiological and structural changes that limit aerobic capacity in HF. In HF, aerobic capacity is measured as peak \( \dot{V}O_2 \), as opposed to the \( \dot{V}O_{2\text{max}} \) measurement in the healthy population. The measurement of \( \dot{V}O_{2\text{max}} \) requires an individual to reach a plateau of maximum volume of oxygen used; persons with HF are rarely able to reach and sustain this plateau. Peak \( \dot{V}O_2 \) is reduced primarily by impaired cardiac output in both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) (2). Other factors such as endothelial dysfunction leading to vasoconstriction and decreased capacity for aerobic metabolism contribute to the reduction in maximum oxygen uptake in HF (2). These physiological processes are amplified by a positive feedback loop of inflammation and may explain, at least in part, the association between peak \( \dot{V}O_2 \) and the inflammasome-related measures. Further investigation comparing these relationships to age and gender matched healthy controls is needed.

Increased cytokines in HF may contribute to the pathophysiology and disease progression by altering cardiac structure and function. Inflammatory cytokines may also contribute to peripheral alterations in vascular and skeletal muscle function. The cardiovascular, respiratory, and skeletal muscle systems all influence aerobic capacity (2), and the individual contributions of pathophysiological changes in each system to impaired aerobic capacity are difficult to discern. Here we show the relationship between IL-1\( \beta \) and peak \( \dot{V}O_2 \) in a systemic source (plasma), but further investigation into the relationships and mechanisms of inflammatory cytokines in cardiovascular and skeletal muscle tissue is warranted.

In this study, we used a linear regression model to predict peak \( \dot{V}O_2 \) based on markers of inflammation, IL-1\( \beta \) and ASC methylation. However, the linear relationship would be the same had we used peak \( \dot{V}O_2 \) to predict inflammation. While we cannot determine if inflammation is a driver of decreased aerobic capacity, if decreased aerobic capacity is a driver of increased inflammation, or if there is a causal relationship at all, the linear association between peak \( \dot{V}O_2 \) and IL-1\( \beta \) suggests that changes in these physiological measures occur together. Low aerobic capacity is a powerful predictor of premature morbidity and higher mortality in HF (7), and adding IL-1\( \beta \) levels may provide better prediction of adverse outcomes in HF. Previously we demonstrated that ASC methylation, protein, and mRNA expression are predictors of clinical events in HF (10). Taken together, this further implicates the inflammasome pathway in the pathophysiological processes of HF. Modification of inflammation via epigenetic modulation may be a novel target for intervention in HF.

Moderate intensity aerobic exercise, such as a walking program, has been shown to increase ASC methylation (25), however these exercise-induced epigenetic changes have not been correlated with circulating cytokines, such as IL-1\( \beta \) or IL-18, or assessed in persons with HF. Aerobic exercise has been shown to be beneficial for most HF patients by altering the deleterious peripheral and central mechanisms, such as inflammatory cytokines, that
contribute to HF exacerbations, worsened symptom severity, and poor clinical outcomes (12, 26). In addition, aerobic exercise reduces vascular resistance and improves endothelial function as well as the oxidative capacity of peripheral muscles, without worsening left ventricular remodeling (12, 26). The HF-ACTION trial (27) established the safety and efficacy of moderate-intensity aerobic exercise in patients with stable HF. Aerobic exercise has been shown to reduce inflammatory cytokines, but further studies are needed to establish the effect of aerobic exercise on ASC methylation and IL-1β in persons with HF.

Limitations

This study was cross-sectional with a relatively small sample size of 54 participants. A larger study following changes in VO₂ and ASC methylation over time may shed more light on the dynamic relationship between these measures. ASC methylation and cytokine analysis was performed using collected whole blood. While peripheral blood mononuclear cells (PBMCs) and serum cytokine levels are indicative of systemic inflammation, including cardiac and/or skeletal muscle biopsy samples would provide more insight into localized inflammatory changes affecting aerobic capacity. In addition, percent DNA methylation of ASC was measured in pooled PBMCs; differences in ASC methylation among participants may reflect varying proportions of cell subsets or epigenetic changes in varying proportions of cells. Further, healthy controls were not included in the study for comparison.

Conclusion

Mean percent ASC methylation and plasma IL-1β levels are associated with peak VO₂ in persons with HF. This suggests inflammasome activation may play a role in determining aerobic capacity in persons with HF. ASC methylation is a potentially modifiable mechanism of reducing inflammation and improving functional capacity in HF. Future research examining modification of ASC expression, such as exercise interventions that increase ASC methylation, may improve aerobic capacity in persons with HF.

Acknowledgments

Supported in part by National Institutes of Health National Institute of Nursing Research grant number 1P30NR014134-01 (Co-investigator – R. Gary), the Heart Failure Society of America Nursing Research Grant (PI – B. Butts), and by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award number UL1TR000454 (PI – D. Stephens).

Effort for B. Butts was funded in part by the National Institutes of Health National Institute of Nursing Research grant numbers T32NR012715 (PI – S. Dunbar) and 1F31NR015180-01 (PI – B. Butts).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References


Figure 1. Peak VO₂ is Associated with ASC Methylation and Interleukin-1β

Peak VO₂ was positively associated with mean percent ASC methylation (left, $r=.47$, $p=.001$).

Peak VO₂ was negatively associated with IL-1β (right, $r=-.38$, $p=.007$).
Table 1
Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N=54</th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59.46</td>
<td>59.46 ± 9.7</td>
<td>40 – 75</td>
</tr>
<tr>
<td>Ejection Fraction (%)</td>
<td>34.</td>
<td>34. ± 14.8</td>
<td>15 – 65</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.37</td>
<td>31.37 ± 6.8</td>
<td>19.1 – 49.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>28</td>
<td>51.9%</td>
</tr>
<tr>
<td>African American</td>
<td>32</td>
<td>59.3%</td>
</tr>
<tr>
<td>β-Blocker use</td>
<td>46</td>
<td>86.8%</td>
</tr>
<tr>
<td>ACE inhibitor use</td>
<td>23</td>
<td>45.6%</td>
</tr>
<tr>
<td>ARB use</td>
<td>13</td>
<td>24.1%</td>
</tr>
<tr>
<td>Diuretic use</td>
<td>45</td>
<td>83.3%</td>
</tr>
<tr>
<td>Pacer/ICD Device</td>
<td>30</td>
<td>55.6%</td>
</tr>
<tr>
<td>College Education</td>
<td>27</td>
<td>50.0%</td>
</tr>
</tbody>
</table>

HFReF = Heart failure with reduced ejection fraction
BMI = Body mass index
ACE = Angiotensin converting enzyme
ARB = Angiotensin receptor blocker
Table 2
Physical Measures by Gender (Mean ± SD)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Total N=54</th>
<th>Females n=28</th>
<th>Males n=26</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak VO$_2$ (ml/kg/min)</td>
<td>16.68 ± 4.7</td>
<td>14.59 ± 3.6</td>
<td>18.85 ± 4.8</td>
<td>.001</td>
</tr>
<tr>
<td>Total Treadmill Time (minutes)</td>
<td>8.27 ± 4.4</td>
<td>6.16 ± 3.0</td>
<td>10.58 ± 4.5</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Six Minute Walk Test (meters)</td>
<td>348.9 ± 78.2</td>
<td>338.77 ± 76.7</td>
<td>359.81 ± 79.9</td>
<td>.33</td>
</tr>
</tbody>
</table>
### Table 3
ASC and Cytokines

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASC Methylation (%)</td>
<td>5.84 ± 0.8</td>
<td>1.33 – 6.82</td>
</tr>
<tr>
<td>IL-1β (pg/mL)</td>
<td>1.72 ± 0.8</td>
<td>0 – 5.18</td>
</tr>
<tr>
<td>IL-18 (pg/mL)</td>
<td>158.49 ± 56.2</td>
<td>96.2 – 333.1</td>
</tr>
</tbody>
</table>

ASC = apoptosis associated speck-like protein with a caspase recruitment domain
IL = interleukin
Table 4
Linear Associations Between Clinical/Demographic Characteristics and ASC and Interleukin-1β

<table>
<thead>
<tr>
<th>N=54</th>
<th>ASC</th>
<th>IL-1β</th>
</tr>
</thead>
</table>
| ASC  | Pearson's r 1 | -.443 **
|      | Sig. (2-tailed) | -.001 |
| IL-1β| Pearson's r -.443 ** | 1 |
|      | Sig. (2-tailed) | .001 |
| Age  | Pearson's r .059 | -.026
|      | Sig. (2-tailed) | .691 .849|
| Female | Pearson's r .042 | .240
|       | Sig. (2-tailed) | .813 .081 |
| AA/Black | Pearson's r -.188 | .218
|         | Sig. (2-tailed) | .213 .114 |
| BMI   | Pearson's r -.048 | .111
|       | Sig. (2-tailed) | .732 .425 |
| β-blocker | Pearson's r -.03 | .006
|         | Sig. (2-tailed) | .841 .966 |
| ACEi  | Pearson's r -.227 | .031
|       | Sig. (2-tailed) | .138 .843 |
| ARB   | Pearson's r -.038 | -.066
|       | Sig. (2-tailed) | .811 .679 |
| Diuretic | Pearson's r -.160 | .096
|        | Sig. (2-tailed) | .273 .514 |
| Pacer/ICD | Pearson's r -.131 | .028
|         | Sig. (2-tailed) | .322 .844 |
| Hypertension | Pearson's r -.222 | .156
|          | Sig. (2-tailed) | .107 .260 |
| Dyslipidemia | Pearson's r .123 | -.156
|           | Sig. (2-tailed) | .374 .259 |
| Depression | Pearson's r .098 | -.161
|           | Sig. (2-tailed) | .479 .245 |
| Diabetes Mellitus | Pearson's r -.200 | .028
<p>|           | Sig. (2-tailed) | .147 .839 |</p>
<table>
<thead>
<tr>
<th>Previous MI</th>
<th>Pearson's r</th>
<th>ASC</th>
<th>IL-1β</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-0.063</td>
<td>0.648</td>
<td>0.140</td>
</tr>
</tbody>
</table>

ASC = apoptosis associated speck-like protein with a caspase recruitment domain  
IL = interleukin  
AA = African American  
BMI = Body mass index  
ACEi = Angiotensin converting enzyme inhibitor  
ARB = Angiotensin receptor blocker  
ICD = Implantable cardioverter defibrillator  
MI = Myocardial Infarction

** Significant (sig.) at p<.05 using 2-tailed bivariate Pearson correlation analysis.
Table 5
Multivariate Analysis of Predictors of Aerobic Capacity

<table>
<thead>
<tr>
<th>Variable</th>
<th>β</th>
<th>β</th>
<th>95% CI</th>
<th>Model 1&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Model 2&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>0.44</td>
<td>4.35</td>
<td>[-4.41, 13.10]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% ASC Methylation</td>
<td>2.73**</td>
<td>2.30**</td>
<td>[0.91, 3.70]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF</td>
<td>-0.78*</td>
<td></td>
<td>[-0.15, -0.002]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender&lt;sup&gt;†&lt;/sup&gt;</td>
<td>2.42*</td>
<td></td>
<td>[0.07, 4.76]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R²</td>
<td>.22</td>
<td>.40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>12.90**</td>
<td>9.72***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔR²</td>
<td>.18</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔF</td>
<td>6.54**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aerobic Capacity (Peak VO₂ ml/kg/min)

<table>
<thead>
<tr>
<th>Variable</th>
<th>β</th>
<th>β</th>
<th>95% CI</th>
<th>Model 1&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Model 2&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>20.38***</td>
<td>21.51***</td>
<td>[16.73, 26.29]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>-2.15**</td>
<td>-1.91**</td>
<td>[-3.32, -0.51]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF</td>
<td>-0.085**</td>
<td></td>
<td>[-0.17, -0.004]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender&lt;sup&gt;†&lt;/sup&gt;</td>
<td>2.62*</td>
<td></td>
<td>[0.12, 5.12]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R²</td>
<td>.15</td>
<td>.35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>8.47**</td>
<td>8.20***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔR²</td>
<td>.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔF</td>
<td>6.99**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ASC = apoptosis associated speck-like protein containing a caspase recruitment domain.
LVEF = left ventricular ejection fraction. CI = confidence interval.

* p<.05.
** p<.01
*** p<.001
† Female is coded as 0.

<sup>a</sup> Model 1 is the direct effect of percent ASC Methylation not adjusted for covariates.

<sup>b</sup> Model 2 considered age, gender, six-minute walk test, and BMI covariates for inclusion in the final model in addition to percent ASC Methylation: stepwise variable selection used.
Model 1 is the direct effect of IL-1β not adjusted for covariates.

Model 2 considered age, gender, six-minute walk test, and BMI covariates for inclusion in the final model in addition to IL-1β: stepwise variable selection used.